Capital Impact Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Capital Impact Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-18,088	Closed	-$276K	–	220
2016 Q3	$276K	Hold	18,088	–	–	0.12%	215
2016 Q2	$702K	Hold	18,088	–	–	0.33%	182
2016 Q1	$503K	Buy	18,088 +13,475	+292%	+$449K	0.24%	203
2015 Q4	$248K	Sell	4,613 -8,300	-64%	-$419K	0.12%	245
2015 Q3	$517K	Sell	12,913 -8,605	-40%	-$281K	0.26%	158
2015 Q2	$688K	Hold	21,518	–	–	0.31%	140
2015 Q1	$514K	Buy	+21,518	New	+$482K	0.23%	192

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Impact Advisors's ITCI Position: Q4 2016 in Review

Capital Impact Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2016, closing a stake of 18,088 shares — an estimated $276K sold.

Capital Impact Advisors first reported a position in ITCI in Q1 2015 and held it in 7 quarters. The position peaked at $702K in Q2 2016. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

Capital Impact Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2016 after selling out during the quarter.
Capital Impact Advisors sold 18,088 Intra-Cellular Therapies Inc. shares in Q4 2016, an estimated $276K.
Capital Impact Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 7 quarters.
Capital Impact Advisors's Intra-Cellular Therapies Inc. position peaked at $702K in Q2 2016.
129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on Capital Impact Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.